CISCO-21 - Treat and prevent Long COVID
Research type
Research Study
Full title
Prevention and early treatment of the long-term effects of COVID-19: a randomised clinical trial of resistance exercise.
IRAS ID
294299
Contact name
Colin Berry
Contact email
Sponsor organisation
Greater Glasgow and Clyde, Research and Development Office
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
Many people have long-lasting symptoms after COVID-19, such as breathlessness, fatigue and chest pain. So far, most research studies of treatments for COVID-19 have focused on the life-threatening acute illness. There have been very few studies looking at treatments to improve long-term health after COVID-19.\n\nCOVID-19, particularly when this requires a hospital admission, can lead to weight loss and muscle wasting. Muscle strengthening (resistance-based) exercise could improve outcomes in the long term.\n\nWe are looking to do two things:\n\n1) To undertake a research trial of resistance-based exercise for people recovering from COVID-19. The study will involve 220 patients, half assigned at random (50:50 chance) to the exercise group and half assigned to standard care. The main assessment (primary outcome) is the incremental shuttle walk test, measured in metres achieved, at 3 months. Secondary measures include spirometry, grip strength and questionnaires. A blood sample will be obtained for research purposes. We will also request permission for longer term follow-up of health records and record linkage( funding dependent)- a submission to the Public Benefit & Privacy Panel (PBPP) will be made prior to any Record linkage.\n\n2) Develop a process for creating a platform for future trials of new treatments after COVID-19. This will cut the costs of doing future trials, and allow more patients the opportunity to contribute to medical research that will help improve outcomes for people recovering from COVID-19.\n\nOur team is multidisciplinary, multi-ethnic, gender-balanced and drawn from across NHS Scotland, and the University of Glasgow. We are currently leading the Cardiovascular Imaging in SARS-CoV-2 (CISCO-19) study, funded by the Chief Scientist Office, in the West of Scotland, using medical imaging of the hearts, lungs, and kidneys of patients, to understand the impact of COVID-19. We have consulted with members of the public, including people with COVID-19, in designing this study.
REC name
West of Scotland REC 5
REC reference
21/WS/0034
Date of REC Opinion
7 Apr 2021
REC opinion
Further Information Favourable Opinion